Substance Use Disorders: A Comprehensive Review and Update

February 19-22, 2023

Lake Buena Vista, FL

SUNDAY, FEBRUARY 19, 2023

2:00 – 6:00 PM              Buprenorphine (MAT) Waiver Training

Laura G. Kehoe, MD, MPH, FASAM

THIS IS A TICKETED EVENT, NO CME CREDIT

Important: Buprenorphine (MAT) Waiver Training Registrants 

You will need to create an account in the PCSS system ahead of the live training.  If you do not set up an account and enroll in your training ahead of time, it will delay your ability to complete the online half and receive their certificate of completion. Please use this link to create an account https://education.sudtraining.org/Public/Registration.aspx Once you have created an account in the PCSS system, please use this link to enroll in the online half of this course: https://education.sudtraining.org/Users/InvitationCode.aspx You will submit this code: WAIVER-250359-11951

Once you have entered the invitation code, click “Get Started”, you will have access to the online half of the training. You may complete the online half before or after our live training. After the live training our staff will indicate your attendance. Once both halves of the training are complete you may return to the PCSS platform, complete their evaluation and claim your waiver training certificate.

Effective December 29, 2022, with the signing of the Consolidated Appropriations Act of 2023 (the Act):

• All DEA registrants should be aware of the following:
• A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.
• Going forward, all prescriptions for buprenorphine only require a standard DEA registration number. The previously used DATA-Waiver registration numbers are no longer needed for any prescription.
• There are no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.
• The Act does not impact existing state laws or regulations that may be applicable.

While no longer required, the Act also introduced new training requirements for all prescribers who are not board certified in addiction medicine. These requirements will go into effect June 21, 2023, and the DEA and SAMHSA are actively working to provider further guidance.

As such, the MGH Psychiatry Academy welcomes all providers who plan to treat patients with opioid use disorder to make use of existent waiver trainings and other educational resources. Please continue to check https://www.samhsa.gov/medication-assisted-treatment/removal-data-waiver-requirement for further updates and guidance.

MONDAY, FEBRUARY 20, 2023

8:00 – 8:10 AM             Welcome & Introduction

David H. Rubin, MD

MODULE TOPIC 1: TREATMENT IN CONTINUING CARE

8:10 – 8:30 AM              Motivational Interviewing

                                    John F. Kelly, PhD

8:30 – 8:50 AM             CBT

John F. Kelly, PhD

8:50 – 9:10 AM             Helping Family Members

John F. Kelly, PhD

9:10 – 9:30 AM             Screening Assessment & Patient Monitoring

Eugene Lambert, MD

9:30 – 10:10 AM            Panel Discussion

Moderator: David Rubin, MD

Panelists: John F. Kelly, PhD, Eugene Lambert, MD

10:10 – 10:30 AM           Coffee Break

MODULE TOPIC 2: GENERAL PRINCIPLES & CARE DELIVERY

10:30 – 10:50 AM           Treating Addiction as a Chronic Disease

                                            Jessica Gray, MD

10:50 – 11:10 AM           Harm Reduction

                                    Justin Alves, RN, MSN, ACRN, CARN, CNE

11:10 – 11:30 AM            Treating Addiction in Relation to Regulatory Agencies

                                    Laura G. Kehoe, MD, MPH, FASAM

11:30 – 12:10 PM           Panel Discussion

Moderator: John Kelly, PhD

Panelists: Jessica Gray, MD, Justin Alves, RN, MSN, ACRN, CARN, CNE

12:10 – 1:10 PM             Lunch Break

MODULE TOPIC 3: RECOVERY SUPPORT SERVICES

1:10 – 1:30 PM               Self-Help Treatments

John F. Kelly, PhD

1:30 – 1:50 PM              Recovery Coaching & Residences
Justin Alves, RN, MSN, ACRN, CARN, CNE

1:50 – 2:10 PM             Panel Discussion

Moderator: John Kelly, PhD
Panelists: Justin Alves, RN, MSN, ACRN, CARN, CNE

2:10 – 2:30 PM              Coffee Break

MODULE TOPIC 4: OPIOID

2:30 – 2:50 PM             Buprenorphine 101

Laura G. Kehoe, MD, MPH, FASAM

2:50 – 3:10 PM             Buprenorphine: low dose inductions and extended release

                                          Eugene Lambert, MD

3:10 – 3:30 PM             Naltrexone Intramuscular & Methadone

Laura G. Kehoe, MD, MPH, FASAM

3:30 – 3:50 PM              Pregnancy

                                      Jessica Gray, MD

3:50 – 4:30 PM              Panel Discussion

Moderator: Laura G. Kehoe, MD, MPH, FASAM

Panelists: Jessica Gray, MD, Eugene Lambert, MD

4:30 PM                      Adjourn  

TUESDAY, FEBRUARY 21, 2023

8:00 – 8:10 AM              Welcome & Introduction

Timothy E. Wilens, MD

MODULE TOPIC 5: NEUROSCIENCE

8:10– 8:30 AM               Neurobiology of Addiction

Timothy E. Wilens, MD

8:30 - 8:50 AM              Genetics of Substance Use Disorders

Robert R. Althoff, MD, PhD

8:50 – 9:10 AM             Evolutionary Theories of Substance Use

                                    David H. Rubin, MD

9:10 – 9:30 PM              Coffee Break

MODULE TOPIC 6: ALCOHOL, SEDATIVES & HYPNOTICS

9:30 - 9:50 AM              Alcohol 

Vinod Rao, MD, PhD

9:50 – 10:10 AM            Alcohol Part II

Vinod Rao, MD, PhD

10:10 – 10:30 AM           Sedatives & Hypnotics

Robert R. Althoff, MD, PhD

10:30 – 10:50 AM           Benzodiazepines & Addiction

Timothy Wilens, MD

10:50 – 11:10 AM           Alcohol & Hepatitis

Eugene Lambert, MD

11:10 – 11:50 AM            Panel Discussion

Moderator: Jessica Gray, MD,

Panelists: Vinod Rao, MD, PhD, Robert R. Althoff, MD, PhD, Timothy Wilens, MD, Eugene Lambert, MD

11:50 – 12:50 PM           Lunch Break

MODULE TOPIC 7: Polysubstance Use

12:50 – 1:10 PM             Fundamentals of Polysubstance Use
Timothy E. Wilens, MD

1:10 – 1:30 PM              Polysubstance Use Cases
Laura G. Kehoe, MD, MPH, FASAM

1:30 – 2:10 PM              Panel Discussion
Moderator: Robert R. Althoff, MD, PhD

                                           Panelists: Timothy E. Wilens, MD, Laura G. Kehoe, MD, MPH, FASAM

2:10 – 2:30 PM              Coffee Break

MODULE TOPIC 8: COMORBIDITY

2:30 – 2:50 PM             Mood Disorders

Vinod Rao, MD          

2:50 – 3:10 PM              Pain

                                    Jessica Gray, MD

3:10 – 3:30 PM             ADHD

                                     Timothy Wilens, MD

3:30 – 4:10 PM              Panel Discussion

Moderator: Timothy Wilens, MD

Panelists: Vinod Rao, MD, Robert R. Althoff, MD, PhD, Jessica Gray, MD

4:10 PM                        Adjourn

WEDNESDAY, FEBRUARY 22, 2023

8:00 – 8:10 AM              Welcome & Introduction

David Rubin, MD

MODULE TOPIC 9:  MARIJUANA & SYNTHETICS

8:10 – 8:30 AM              Marijuana 101

                                      Timothy E. Wilens, MD

8:30 – 8:50 AM              Clinical Management

Robert R. Althoff, MD, PhD

8:50 – 9:10 AM             Synthetics, Kratom & Designer Drugs

                                    Timothy E. Wilens, MD

9:10 – 9:50 AM             Panel Discussion

Moderator: David Rubin, MD

Panelists: Robert R. Althoff, MD, PhD, Timothy E. Wilens, MD

9:50 – 10:10 AM            Coffee Break

MODULE TOPIC 10: STIMULANTS

10:10 – 10:30 AM           Inpatient Methamphetamine
Timothy E. Wilens, MD

10:30 – 10:50 AM           Outpatient Methamphetamine 
Justin Alves, RN, MSN, ACRN, CARN, CNE

10:50 – 11:10 AM           Cocaine, Rx Stimulants
Timothy E. Wilens, MD

11:10 – 11:50 AM            Panel Discussion
Moderator: Timothy Willens, MD
Panelists: Justin Alves, RN, MSN, ACRN, CARN, CNE

11:50 AM                      Adjourn